Short Interest in BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Rises By ∞

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) saw a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 111,892 shares, a growth of ∞ from the July 30th total of 0 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 360,667 shares, the days-to-cover ratio is presently 0.3 days.

Insider Activity at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director Bihua Chen acquired 312,500 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the transaction, the director directly owned 3,614,034 shares of the company’s stock, valued at $57,824,544. This represents a 9.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John P. Schmid bought 6,000 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The shares were acquired at an average cost of $16.00 per share, with a total value of $96,000.00. Following the completion of the purchase, the director owned 6,000 shares in the company, valued at approximately $96,000. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 1,573,900 shares of company stock valued at $25,181,900 in the last ninety days.

BlossomHill Therapeutics Stock Down 1.2%

Shares of BLSM opened at $19.56 on Friday. BlossomHill Therapeutics has a 12-month low of $15.25 and a 12-month high of $20.61.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded BlossomHill Therapeutics to a “hold” rating in a research report on Saturday, August 15th.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.